These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Germany is widely recognized as one of the leading countries in the pharmaceutical industry boasting a rich history of innovation cutting-edge research and global influence With its well-established i ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

Bayer today announced topline results of the Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic ...

Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter. Total revenues ...

Compared with the same month last year, the European Union imported significantly more pharmaceutical products from Russia in ...

Health news updates include the EU contemplating curbs on Chinese medical device makers, Pfizer reducing its stake in Haleon, toothpaste lawsuits over fluoride, Eli Lilly’s stock drop, biopharma ...

The company – which, like many pharma groups ... Last year, Bayer launched a dedicated digital consumer health business unit that aims to develop new products that will allow people to take ...

Bayer announces positive results of pivotal phase III QUANTI studies of gadoquatrane, an investigational GBCA for use in magnetic resonance imaging: Berlin Monday, January 13, 202 ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...